公开(公告)号：US07964727B2

公开(公告)日：2011-06-21

申请号：US10595948

申请日：2004-11-10

申请人： Tomoki Kato ,  Kiyoshi Kawamura ,  Mikio Morita ,  Chikara Uchida

发明人： Tomoki Kato ,  Kiyoshi Kawamura ,  Mikio Morita ,  Chikara Uchida

IPC分类号： C07D221/02 ,  C07D215/00 ,  C07D413/00 ,  A01N43/40 ,  A01N43/42 ,  A61K31/435 ,  A61K31/44

CPC分类号： C04B35/632 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14

摘要： This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents α1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1, 2 or 3, or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

摘要翻译： 本发明提供式（I）化合物：其中Het表示具有一个氮原子的杂环基团，B直接与该碳原子结合，并且具有4至7个碳原子，所述杂环基团未被取代或被1至4个取代基取代 独立地选自取代基α1; A表示具有1至4个碳原子的亚烷基; B表示共价键或具有1至5个碳原子的亚烷基; R1表示异丙基，正丙基或环戊基; R2表示甲基，氟原子或氯原子; R3独立地表示（i）氧代基，羟基，氨基，烷基氨基或羧基; （ii）具有3至8个碳原子的环烷基，所述环烷基被1至5个取代基取代，或（iii）具有3至8个原子的杂环基，所述杂环基未被取代或被1 至5个取代基，n为1,2或3，或其药学上可接受的盐。 这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。

公开(公告)号：US07700618B2

公开(公告)日：2010-04-20

申请号：US12280586

申请日：2007-02-23

申请人： Tomoki Kato ,  Kana Kon-I ,  Yohei Yuki ,  Kazuo Ando

发明人： Tomoki Kato ,  Kana Kon-I ,  Yohei Yuki ,  Kazuo Ando

IPC分类号： A61K31/437 ,  A61K31/4184 ,  C07D471/04 ,  C07D235/08

CPC分类号： C07D235/08 ,  C07D235/12 ,  C07D405/12 ,  C07D471/04

摘要： This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis.

摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3，R 4，R 5，m和n各自如本文所述，和含有这些化合物的组合物， 治疗由CB2受体活性介导的病症，例如但不限于炎症性疼痛，伤害性疼痛，神经性疼痛，纤维肌痛，慢性腰痛，内脏痛，急性脑缺血，疼痛，慢性疼痛， 急性疼痛，疱疹后神经痛，神经病，神经痛，糖尿病性神经病，HIV相关神经病，神经损伤，类风湿关节炎疼痛，骨关节炎疼痛，背痛，癌症疼痛，牙痛，纤维肌痛，神经炎，坐骨神经痛，炎症，神经变性疾病，咳嗽 ，支气管收缩，肠易激综合征（IBS），炎性肠病（IBD），结肠炎，脑血管缺血，呕吐如癌症化疗诱发的呕吐，类风湿性关节炎，哮喘，克罗恩病 溃疡性结肠炎，哮喘，皮炎，季节性过敏性鼻炎，GERD，便秘，腹泻，功能性胃肠道疾病，肠易激综合征，皮肤T细胞淋巴瘤，多发性硬化症，骨关节炎，牛皮癣，系统性红斑狼疮，糖尿病，青光眼，骨质疏松症，肾小球性肾炎， 肾缺血，肾炎，肝炎，脑中风，血管炎，心肌梗死，脑缺血，可逆性气道阻塞，成人呼吸道疾病综合征，COPD，隐源性纤维化肺泡炎和支气管炎。

公开(公告)号：US20090137584A1

公开(公告)日：2009-05-28

申请号：US12280586

申请日：2007-02-23

申请人： Tomoki Kato ,  Kana Kon-I ,  Yohei Yuki ,  Kazuo Ando

发明人： Tomoki Kato ,  Kana Kon-I ,  Yohei Yuki ,  Kazuo Ando

IPC分类号： A61K31/5377 ,  C07D235/08 ,  C07D413/12 ,  A61P25/00 ,  A61K31/4184

CPC分类号： C07D235/08 ,  C07D235/12 ,  C07D405/12 ,  C07D471/04

摘要： This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis.

摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3，R 4，R 5，m和n各自如本文所述，和含有这些化合物的组合物， 治疗由CB2受体活性介导的病症，例如但不限于炎症性疼痛，伤害性疼痛，神经性疼痛，纤维肌痛，慢性腰痛，内脏痛，急性脑缺血，疼痛，慢性疼痛， 急性疼痛，疱疹后神经痛，神经病，神经痛，糖尿病性神经病，HIV相关神经病，神经损伤，类风湿关节炎疼痛，骨关节炎疼痛，背痛，癌症疼痛，牙痛，纤维肌痛，神经炎，坐骨神经痛，炎症，神经变性疾病，咳嗽 ，支气管收缩，肠易激综合征（IBS），炎性肠病（IBD），结肠炎，脑血管缺血，呕吐如癌症化疗诱发的呕吐，类风湿性关节炎，哮喘，克罗恩病 溃疡性结肠炎，哮喘，皮炎，季节性过敏性鼻炎，GERD，便秘，腹泻，功能性胃肠道疾病，肠易激综合征，皮肤T细胞淋巴瘤，多发性硬化症，骨关节炎，牛皮癣，系统性红斑狼疮，糖尿病，青光眼，骨质疏松症，肾小球性肾炎， 肾缺血，肾炎，肝炎，脑中风，血管炎，心肌梗死，脑缺血，可逆性气道阻塞，成人呼吸道疾病综合征，COPD，隐源性纤维化肺泡炎和支气管炎。

公开(公告)号：US20080293767A1

公开(公告)日：2008-11-27

申请号：US10597480

申请日：2005-01-18

申请人： Tomoki Kato ,  Kiyoshi Kawamura ,  Chikara Uchida

发明人： Tomoki Kato ,  Kiyoshi Kawamura ,  Chikara Uchida

IPC分类号： A61K31/4545 ,  A61P3/00 ,  A61P25/00 ,  A61P1/00 ,  A61P9/00 ,  C07D405/14 ,  C07D401/12

CPC分类号： C07D401/12 ,  C07D405/14

摘要： This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

摘要翻译： 本发明提供式（I）化合物：其中R 1表示具有1至4个碳原子的烷基或卤原子，R 2表示具有1至4个碳原子的烷基，R 3表示氢原子或羟基 基团，A表示氧原子或式-C（R4）（R5） - （其中R4表示氢原子或具有1至4个碳原子的烷基，R5表示羟基或式 具有1至4个碳原子的烷氧基）或其药学上可接受的盐。 这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。

公开(公告)号：US20080269211A1

公开(公告)日：2008-10-30

申请号：US11995179

申请日：2006-07-14

申请人： Asako Ishibashi ,  Tomoki Kato ,  Kiyoshi Kawamura ,  Sachiko Mihara ,  Mikio Morita

发明人： Asako Ishibashi ,  Tomoki Kato ,  Kiyoshi Kawamura ,  Sachiko Mihara ,  Mikio Morita

IPC分类号： A61K31/416 ,  A61P1/00 ,  A61P25/00 ,  A61P9/00 ,  C07D401/12 ,  C07D405/14 ,  A61K31/5377 ,  C07D403/12 ,  C07D413/14 ,  C07D401/14 ,  A61K31/454

CPC分类号： C07D401/12 ,  C07D403/12 ,  C07D405/14

摘要： This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: R1, R2, R3, A and m are each as described herein and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome.

摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，其中：R 1，R 2，R 3， A和m各自如本文所述，含有这些化合物的组合物和这些化合物在治疗由5-HT 4激动剂活性介导的病症中的用途，例如但不限于胃食管反流 疾病，胃肠道疾病，胃动力障碍，非溃疡性消化不良，功能性消化不良，肠易激综合征（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默氏病，认知障碍，呕吐，偏头痛， 神经疾病，疼痛，心血管疾病，心力衰竭，心律失常，糖尿病和呼吸暂停综合征。

公开(公告)号：US20070155732A1

公开(公告)日：2007-07-05

申请号：US11556523

申请日：2006-11-03

申请人： Kazunari Nakao ,  Yoshiyuki Okumura ,  Miyako Matsumizu ,  Naomi Ueno ,  Yoshinobu Hashizume ,  Tomoki Kato ,  Akiyoshi Kawai ,  Yoriko Miyake ,  Seiji Nukui ,  Katsuhiro Shinjyo ,  Kana Taniguchi

发明人： Kazunari Nakao ,  Yoshiyuki Okumura ,  Miyako Matsumizu ,  Naomi Ueno ,  Yoshinobu Hashizume ,  Tomoki Kato ,  Akiyoshi Kawai ,  Yoriko Miyake ,  Seiji Nukui ,  Katsuhiro Shinjyo ,  Kana Taniguchi

IPC分类号： A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4745 ,  C07D471/02

CPC分类号： C07D213/75 ,  A61K31/00 ,  A61K31/4178 ,  A61K31/437 ,  A61K31/64 ,  C07D231/12 ,  C07D233/56 ,  C07D235/06 ,  C07D235/08 ,  C07D235/12 ,  C07D235/14 ,  C07D235/16 ,  C07D235/18 ,  C07D235/30 ,  C07D249/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D491/04 ,  Y02P20/55

摘要： This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl ; R5 is H, C1-4 alkyl, etc.; Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamadin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐，其中Y 1，Y 2，Y 3和 Y 4独立地选自N，CH等; R 1是H，C 1-8烷基等; Q 1是5-12元单环或双环芳族环，任选地含有至多4个选自O，N和S的杂原子等; A是任选含有至多3个选自O，N和S的杂原子的5-6元单环芳环等; B是任选被氧代基取代的C 1-6亚烷基等; W是NH，O等; R 2是H，C 1-4烷基等; Z是任选地含有至多3个选自O，N和S的杂原子的5-12元单环或双环芳环等; L为卤素，C 1-4烷基等; m为0,1或2; R 3和R 4独立地选自H和C 1-4烷基; R 5是H，C 1-4烷基等; Q 2是5-12元单环或双环芳族环或三环，任选地含有至多3个选自O，N和S的杂原子等。这些化合物可用于治疗介导的医学病症 通过前列腺炎如疼痛，发热或炎症等。本发明还提供包含上述化合物的药物组合物。

公开(公告)号：US06727238B2

公开(公告)日：2004-04-27

申请号：US10465767

申请日：2003-06-18

申请人： Kazuo Ando ,  Tomoki Kato ,  Akiyoshi Kawai ,  Tomomi Nonomura

发明人： Kazuo Ando ,  Tomoki Kato ,  Akiyoshi Kawai ,  Tomomi Nonomura

IPC分类号： A61K3133

CPC分类号： A61K31/422 ,  A61K31/427 ,  A61K31/454 ,  C07C311/39 ,  C07C317/36 ,  C07D207/325 ,  C07D207/333 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

摘要： This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo,, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

摘要翻译： 本发明提供下式的化合物或其药学上可接受的盐，其中A是部分不饱和或不饱和的五元杂环或部分不饱和或不饱和的五元碳环，其中4-（磺酰基）苯基和4-取代的苯基 在式（I）中，与环A相邻的环原子相连; R 1是任选取代的芳基或杂芳基，条件是当A是吡唑时，R 1是杂芳基; R 2是C 1-4烷基，卤素取代的C 1-4烷基，C 1-4烷基氨基，C 1-4二烷基氨基或氨基; R 3，R 4和R 5独立地是氢，卤素，C 1-4烷基，卤素取代的C 1-4烷基等; 或R 3，R 4和R 5中的两个与它们所连接的原子一起形成4-7元环; R 6和R 7独立地是氢，卤素，C 1-4烷基，卤素取代的C 1-4烷基，C 1-4烷氧基，C 1-4烷硫基，C 1-4烷基氨基或N，N-二C1- 4烷基氨基; 并且m和n独立地为1,2,3或4.本发明还提供了可用于治疗前列腺素作为病原体的医学病症的药物组合物。

公开(公告)号：US06608095B2

公开(公告)日：2003-08-19

申请号：US09841348

申请日：2001-04-24

申请人： Kazuo Ando ,  Tomoki Kato ,  Akiyoshi Kawai ,  Tomomi Nonomura

发明人： Kazuo Ando ,  Tomoki Kato ,  Akiyoshi Kawai ,  Tomomi Nonomura

IPC分类号： A61K3141

CPC分类号： C07D207/335 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

摘要： This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

摘要翻译： 本发明提供下式的化合物或其药学上可接受的盐，其中A是部分不饱和或不饱和的五元杂环或部分不饱和或不饱和的五元碳环，其中4-（磺酰基）苯基和4-取代的苯基 在式（I）中，与环A相邻的环原子相连; R1是任选取代的芳基或杂芳基，条件是当A是吡唑时，R 1是杂芳基; R2是C1-4烷基，卤素取代的C1-4烷基，C1-4烷基氨基，C1-4二烷基氨基或氨基; R 3，R 4和R 5独立地为氢，卤素，C 1-4烷基，卤素取代的C 1-4烷基等; 或者R 3，R 4和R 5中的两个与它们所连接的原子一起形成4-7元环; R 6和R 7独立地是氢，卤素，C 1-4烷基，卤素取代的C 1-4烷基，C 1-4烷氧基，C 1-4烷硫基，C 1-4烷基氨基或N，N-二C 1-4烷基氨基; 并且m和n独立地为1,2,3或4.本发明还提供了可用于治疗前列腺素作为病原体的医学病症的药物组合物。

公开(公告)号：US10276637B2

公开(公告)日：2019-04-30

申请号：US14114880

申请日：2012-05-09

申请人： Toshiki Matsumoto ,  Tadahiko Yoshinaga ,  Tomoki Kato ,  Tetsuya Inoue ,  Mitsunori Ito ,  Kei Yoshida ,  Kiyoshi Ikeda ,  Mitsuru Eida

发明人： Toshiki Matsumoto ,  Tadahiko Yoshinaga ,  Tomoki Kato ,  Tetsuya Inoue ,  Mitsunori Ito ,  Kei Yoshida ,  Kiyoshi Ikeda ,  Mitsuru Eida

IPC分类号： H01L27/32 ,  H01L51/00 ,  C09K11/06 ,  H05B33/10 ,  H01L51/50

摘要： An organic EL multi-color emitting device including a substrate, and a first light-emitting element and a second light-emitting element arranged on the surface of the substrate; the first light-emitting element including, between an anode and a cathode, a first organic layer, a second organic layer and a third organic layer in this sequence in a direction perpendicular to the surface of the substrate; the second light-emitting element including, between an anode and a cathode, a second organic layer and a third organic layer in this sequence in a direction perpendicular to the surface of the substrate; the first organic layer including a first light-emitting dopant; the third organic layer including a second light-emitting dopant; the second organic layer including any of (A) a compound including an arylamine site, and a furan site or a thiophene site, (B) a compound including an arylamine site and a site comprising a nitrogen-containing six-membered ring structure, (C) a compound including a carbazole site, and a furan site or a thiophene site, and (D) a compound including a carbazole site and a site including a nitrogen-containing six-membered ring structure.

公开(公告)号：US09527814B2

公开(公告)日：2016-12-27

申请号：US13496400

申请日：2011-02-15

申请人： Tomoki Kato ,  Mitsuru Eida ,  Masami Watanabe ,  Akinori Yomogita ,  Takushi Shiomi

发明人： Tomoki Kato ,  Mitsuru Eida ,  Masami Watanabe ,  Akinori Yomogita ,  Takushi Shiomi

IPC分类号： H01L51/50 ,  C07D209/86 ,  C07D307/91 ,  C07D407/14 ,  C09K11/06 ,  H01L51/00 ,  H05B33/14

CPC分类号： C07D209/86 ,  C07D307/91 ,  C07D407/14 ,  C09K11/06 ,  C09K2211/1029 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5048 ,  H05B33/14

摘要： An aromatic amine derivative represented by the following formula (1), wherein L is a linking group, Z is a group represented by the following formula (2) and A1 and A2 are independently a monovalent group represented by the following formula (3):

摘要翻译： 由下式（1）表示的芳香族胺衍生物，其中L为连接基团，Z为下式（2）表示的基团，A1和A2分别为下式（3）表示的一价基团：